featured
A Phase I, Open Label, Dose Escalation Study to Evaluate the Safety and Immune Activation of Adv-GM-CAIX Transduced Dendritic Cells in Patients With Metastatic Kidney Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.